Clinical trial NCT00003135: Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer
Official title: A Phase I-II Trial of Mild Whole-Body Hyperthermia Combined With Liposomal Doxorubicin/5-Fluorouracil in Patients With Advanced Malignancy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Breast Cancer
Cervical Cancer
Endometrial Cancer
Ovarian Cancer
Keywords: stage IV breast cancer
recurrent breast cancer
recurrent cervical cancer
stage IVB cervical cancer
stage IVA cervical cancer
stage IV ovarian epithelial cancer
recurrent ovarian epithelial cancer
stage IV endometrial carcinoma
recurrent endometrial carcinoma
stage IV ovarian germ cell tumor
recurrent ovarian germ cell tumor
male breast cancer
Lead sponsor: National Cancer Institute (NCI)
Sponsor class: NIH
First posted: 2003-01-27
Enrollment: 34
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above body temperature. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with hyperthermia may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving fluorouracil and liposomal doxorubicin together with systemic hyperthermia works in treating patients with metastatic breast, ovarian, endometrial, or cervical cancer.

Detailed description: OBJECTIVES:

* Evaluate tumor response and toxicity induced by fluorouracil and doxorubicin HCl liposome combined with mild systemic hyperthermia in patients with metastatic breast, ovarian, endometrial, or cervical cancer.

OUTLINE: This is a time-escalation study of systemic hyperthermia.

Patients receive fluorouracil IV continuously over 24 hours on days 1-5 and doxorubicin HCl liposome IV over 30 minutes on day 6. Beginning on day 7, patients receive heat applied for 6-24 hours (in 6-hour sequential treatments) using a mild hyperthermia-induction device. Treatment repeats every 4-5 weeks for a total of 4 courses. Patients who achieve less than a complete response but have no disease progression may receive additional courses of chemotherapy alone.

Cohorts of 5 patients receive escalating durations of hyperthermia until the recommended phase II duration is determined. The recommended phase II duration of hyperthermia is defined as the level preceding that at which 1 of 5 patients experiences measurable toxicity. (Phase I closed as of 9/28/01)

Patients are followed at 4 weeks and then every 6 months for 1 year.

PROJECTED ACCRUAL: A maximum of 34 patients will be accrued for this study within 48 months.

Eligibility criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed metastatic breast, ovarian, endometrial, or cervical carcinoma
* Measurable and evaluable disease
* No brain metastases
* No hepatic involvement greater than 80%
* No lung involvement greater than 30%
* Hormone receptor status:

  * Not specified

PATIENT CHARACTERISTICS:

Age:

* 18 and over

Sex:

* Not specified

Menopausal status:

* Not specified

Performance status:

* Zubrod 0-2

Life expectancy:

* At least 12 weeks

Hematopoietic:

* Absolute granulocyte count greater than 1,500/mm\^3
* Platelet count greater than 90,000/mm\^3
* Normal bone marrow cellularity on bone marrow biopsy
* Thrombin time less than 17 sec
* Fibrinogen greater than 200 mg/dL
* FSP less than 40
* No coagulopathy

Hepatic:

* Bilirubin less than 2.0 mg/dL
* SGPT less than 2 times normal
* PT less than 14 sec
* PTT less than 35 sec

Renal:

* BUN less than 25 mg/dL
* Creatinine clearance at least 45 mL/min

Cardiovascular:

* Normal cardiovascular system
* Resting ventricular ejection fraction greater than 40%
* No prior myocardial infarction
* No symptomatic coronary artery disease
* No unstable blood pressure
* No thromboembolic disease

Neurologic:

* No seizures or other CNS disorders
* Negative computerized tomographic scan of brain

Pulmonary:

* FEV_1 greater than 70% of predicted
* Arterial pressure of oxygen greater than 60 mmHg on room air with appropriate pressure of carbon dioxide and pH values
* No history of cardiopulmonary or respiratory disease

Other:

* No other serious concurrent medical illness
* No diabetes mellitus

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* Not specified

Chemotherapy:

* Prior chemotherapy allowed

Endocrine therapy:

* No adrenal corticosteroids

Radiotherapy:

* Not specified

Surgery:

* Not specified

Other:

* No concurrent cardiac glycosides, antianginal therapy, or antiarrhythmics
* No concurrent vasodilators, anticoagulants, thrombolytic agents, or aspirin

Primary outcomes:
measure: Tumor response
measure: Toxicity
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: University of Texas Health Science Center at Houston
state: Texas
Study officials:
affiliation: The University of Texas Health Science Center, Houston
name: Joan M.C. Bull, MD
role: STUDY_CHAIR
References: